Lawsuit filed for Investors who lost money with Metagenomi, Inc. (NASDAQ: MGX) in its IPO

An investor, who purchased shares of Metagenomi, Inc. (NASDAQ: MGX), filed a lawsuit over alleged violations of Federal Securities Laws by Metagenomi, Inc. in connection with certain allegedly false and misleading statements made between February 9 and 13, 2024.

Investors who purchased a significant amount of shares of Metagenomi, Inc. (NASDAQ: MGX) between February 9 and 13, 2024, have certain options and for certain investors are short and strict deadlines running. Deadline: November 25, 2024. NASDAQ: MGX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Emeryville, CA based Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States.

On February 12, 2024, Metagenomi, Inc. conducted its initial public offering ("IPO"). The Company sold about 6.25 million shares at $15 per share as part of the IPO.

Then on May 1, 2024, Metagenomi, Inc. announced that it and Moderna had "mutually agreed to terminate their collaboration" agreement. An analyst reported on the announcement, noting that the news was surprising, as was its timing. The analyst also noted that the partnership Metagenomi had with Moderna was a critical part of the core thesis and that losing this partnership during this early stage in development raised more questions than answers.
Shares of Metagenomi, Inc. (NASDAQ: MGX) declined to as low as $2.76 per share on August 09, 2024.

The plaintiff alleges on behalf of purchasers who purchased Metagenomi, Inc. (NASDAQ: MGX) shares pursuant and/or traceable to Metagenomi's registration statement for the initial public offering held between February 9 and 13, 2024, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between February 9 and 13, 2024, the Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. The action seeks to compensate the Class members and recover the damages they sustained because of Defendants' allegedly false and misleading statements.

Those who purchased shares of Metagenomi, Inc. (NASDAQ: MGX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.